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A B S T R A C T
Background
As estrogens have been shown to have several potentially beneficial effects on the central nervous system, it is biologically plausible that
maintaining high levels of estrogens in postmenopausal women by means of estrogen replacement therapy (ERT) could be protective
against cognitive decline in women with Alzheimer’s disease (AD) or other dementia syndromes.
Objectives
To investigate the effects of ERT (estrogens only) or HRT (estrogens combined with a progestagen) compared with placebo in
randomized controlled trials (RCTs) on cognitive function of postmenopausal women with dementia.
Search methods
TheCochraneDementia andCognitive ImprovementGroup SpecializedRegister, which contains records frommanymedical databases,
The Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO and LILACS were searched on 7 November 2007 using the terms
ORT, PORT, ERT, HRT, estrogen*, oestrogen* and progesterone*.
Selection criteria
All double-blind randomized controlled trials (RCTs) into the effect of ERT or HRT for cognitive function with a treatment period of
at least two weeks in postmenopausal women with AD or other types of dementia.
Data collection and analysis
Abstracts of the references retrieved by the searches were read by two reviewers (EH and KY) independently in order to discard those
that were clearly not eligible for inclusion. The two reviewers studied the full text of the remaining references and independently selected
studies for inclusion. Any disparity in the ensuing lists was resolved by discussion with all reviewers in order to arrive at the final list
of included studies. The selection criteria ensured that the blinding and randomization of the included studies was adequate. The two
reviewers also assessed the quality of other aspects of the included trials. One reviewer (EH) extracted the data from the studies, but
was aided and checked by JB from Cochrane.
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Main results
A total of seven trials including 351 women with AD were analysed. Because different drugs were used at different studies it was not
possible to combine more than two studies in any analysis.
On a clinical global rating, clinicians scored patients taking CEE as significantly worse compared with the placebo group on the Clinical
Dementia Rating scale after 12 months (overall WMD = 0.35, 95% CI = 0.01 to 0.69, z = 1.99, P < 0.05).
Patients taking CEE had a worse performance on the delayed recall of the Paragraph Test (overall WMD = -0.45, 95% CI = -0.79
to -0.11, z = 2.60, P < 0.01) after one month than those taking placebo. They had a worse performance on Finger Tapping after 12
months (WMD = -3.90, 95% CI = -7.85 to 0.05, z = 1.93, P < 0.05).
Limited positive effects were found for the lower dosage of CEE (0.625 mg/day) which showed a significant improvement in MMSE
score only when assessed at two months, and disappeared after correction for multiple testing. No significant effects for MMSE were
found at longer end points (3, 6 and 12 months of treatment). With a dosage of 1.25 mg/d CEE, short-term significant effects were
found for Trial-Making test B at one month and Digit Span backward at four months. After two months of transdermal diestradiol
(E2) treatment, a highly significant effect was observed for the word recall test (WMD = 6.50, 95% CI = 4.04 to 8.96, z = 5.19, P <
0.0001). No other significant effects were found for other outcomes measured.
Authors’ conclusions
Currently, HRT or ERT for cognitive improvement or maintenance is not indicated for women with AD.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence of a positive effect that estrogen replacement therapy can maintain cognitive function for a longer period
of time (> five months) in women with Alzheimer’s disease
After the menopause, in women levels of estrogens decline. Estrogen replacement therapy (ERT) or replacement therapy with both
estrogens and progestagens (hormone replacement therapy or HRT) might theoretically help to maintain cognitive function in post-
menopausal women with dementia. We therefore investigated the results of randomized controlled trials of the effects of ERT and
HRT on cognitive function in postmenopausal women with AD.
Overall, however, there was no evidence for positive effects of ERT or HRT which was sustained after two months of treatment. This
is similar to results of studies of ERT and HRT in women without dementia, which additionally found that HRT increases the rate of
dementia in women over 65 years.
B A C K G R O U N D
Nearly all cognitive functions decline, on average, with age, but
there is a large variability which ranges from “successful” aging
to dementia (Huppert 1997). The determinants of this variability
are uncertain but elderly women seem to have a higher risk of
developing Alzheimer’s disease (AD) than elderly men (Launer
1999). While this may be because they reach an older age, and
aging is a risk factor for AD, the age-specific incidence of AD is
also higher in women than in men (Fratiglioni 2000). It has been
suggested that sex steroid hormone deficiencies in elderly women
may play a role in this difference.
Estrogens (UK spelling oestrogens) are steroid hormones produced
in women by the ovaries. The estrogen-producing cells become
depleted at menopause, and postmenopausal women have much
lower estrogen levels than men. In men, and in women after the
menopause, the main source of estrogens is from conversion of
circulating androgen steroid hormone precursors. In women, the
main source of androgen steroids are the ovaries (theca cells) and
the adrenal cortex, whereas in men it is the testes. Estrogens have
an important role in the female reproductive cycle, but animal and
in vivo cell studies have suggested that estrogens can have benefi-
cial effects on brain structures including those related to memory,
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such as the hippocampus and basal cholinergic forebrain (McEwen
1997). There appear to be a variety of mechanisms involved in
this process, including anti-amyloidgenic effects, antioxidant ef-
fects, dendritic sprouting and effects on various neurotransmitters
involved in cognitive function (Silva 2001; McEwen 1997).
It is possible that maintaining high levels of estrogens in post-
menopausal women by means of estrogen replacement therapy
(ERT) or combined therapy with estrogens and progestagens (hor-
mone replacement therapy - HRT) could be protective against
cognitive decline and the development of AD or other dementia
syndromes. Post-menopausal ERT orHRT is usually prescribed to
treat menopausal symptoms, such as hot flashes (UK hot flushes)
and night sweats. For hysterectomized postmenopausal women,
replacement therapy is usually given as ERTbutHRT is prescribed
for postmenopausal women with a uterus to reduce the risk of
endometrial hypertrophy and cancer. ERT use has been associ-
ated with an increased risk of breast as well as uterine cancer (but
see Col 2001) and after the results of WHIMS were published
(Shumaker 2003; Shumaker 2004), paradoxically now also with a
doubled risk of dementia in women > 65 years (see discussion).
Most observational studies, however, suggested that the use of ERT
and HRT is associated with a decreased risk of AD (Hogervorst
2000; Yaffe 1998a), but observational studies are subject to bias
(Barrett-Connor 1991). For instance, women who choose to use
ERT or HRT after the menopause in general have a higher educa-
tion, healthier life-styles and are also healthier before using ERT
or HRT than women who do not chose to use ERT or HRT
(Matthews 1996). Taking ERT or HRT is thus associated with a
healthier life style, which in turn candecrease the risk for dementia.
In addition, despite estrogen’s biologically plausible mechanisms
for protecting the aging brain, two earlier reviews concluded that
the human studies had substantial methodological problems and
had produced conflicting results (Hogervorst 2000; Yaffe 1998a).
The present review assesses the evidence for effectiveness of ERT
or HRT in treating the cognitive impairments of postmenopausal
women with dementia. The evidence for effects of ERT or HRT
on cognitive function in healthy postmenopausal women has been
the subject of another review (Lethaby 2008).
Refer to Appendix 1 for a full list of abbreviations and their defi-
nitions.
O B J E C T I V E S
To assess the effects of hormone replacement therapy consisting
of estrogens alone (ERT) or in combination with a progestagen
(HRT) on cognitive function in women with dementia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomized placebo-controlled trials (RCTs) were included in
which treatment with ERT or HRT was administered to women
with dementia to maintain cognitive function for at least two
weeks. Trials in which the allocation to treatment or control was
not randomized, or in which treatment allocation was not con-
cealed, were excluded. This is because prior knowledge of treat-
ment allocation may lead to biased patient allocation (Schulz
1995).
Types of participants
Postmenopausal women who had been diagnosed as having
Alzheimer’s disease or other dementia syndromes by standard
consensus-based criteria, such as ICD-10, DSM (APA 1999) or
NINCDS/ADRDA (McKhann 1984). Postmenopausal statuswas
defined as established six months after the last menstrual period.
Types of interventions
Interventions containing estrogens alone (ERT) or when com-
bined with a progestagen (HRT). All doses and dosing schedules
and any mode of administration - oral, subdermal, transdermal or
intravenous - were considered.
Most commonly used ERTs are:
CEE = conjugated equine estrogens: given orally in dosages of
0.625 or 1.25 mg per day (apparently also in 0.3 mg/day) which
contains E1-S = estrone sulphate;
E2 = estradiol: usually given transdermally (0.1 to 0.05 mg e.g.
Asthana 1999) or intramuscularly (2 mg/week, e.g. McDonald
Caldwell 1952);
Sometimes estrogens are given in combination with a progestagen
(HRT) which is usually MPA = medroxyprogesteroneacetate or
P = progesterone (McDonald Caldwell 1952; Honjo 1995; Birge
1997) to protect women with a uterus against endometrial hyper-
plasia and malignancies. This treatment regimen could be sequen-
tial or continuous and all dosages were considered.
Types of outcome measures
The primary outcome of interest was cognitive function, split into
the more specific following categories:
General cognitive function tests
The Mini-Mental Status Examination (MMSE), the Blessed In-
formation, Memory and Concentration Test (BIMC), and the
Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-
Cog). In two studies (Honjo 1995; Zhang 2006) the Hasegawa
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Dementia Scale (HSD) was used as a test of general cognitive func-
tion.
Verbal memory tests
Paragraph recall or Logical Memory from the Wechsler Mem-
ory Scale (WMS); Paired Associate Learning (WMS); word lists:
Buschke Selective Reminding Test (BSRT); CERAD 10 word list
recall; verbal category Fluency tests for semantic memory; Digit
Span forward for short term memory storage
Visual memory tests
Visual Retention tests (VRT fromWMS): immediate and delayed
recall; visual span; face recognition; the modified Rey-Osterich
Visual Memory Test
Language tests
Boston Naming Test, Token test
Speed and efficiency of information processing and
concentration tests
Trail Making Test, part A (TMT-A), Digit Symbol Substitution
Test (DSST), letter cancellation test; and executive function or
controlled information processing tests: Stroop interference test,
Trail Making Test part B (TMT-B), Digit Span backward. On
most of the speed tests, a stronger drop in the time needed to
respond indicates a positive result.
As secondary outcome measures, subjective scales of clinical
change (a positive results indicates a worsening) and mood or de-
pression were included:
Clinical impression of change scales
Clinician Interview-Based Impression of Change (CIBIC), Clin-
ical Dementia Rating scale (CDR), Clinician’s Global Impression
of Change (CGIC)
Depression scales
Hamiliton Depression Rating Scale (HDRS).
In this respect, the FDA standard tests for AD trials are the ADAS-
Cog and CIBIC and these should perhaps be used in future trials
for comparability.
Search methods for identification of studies
See Cochrane Dementia and Cognitive Improvement Group
methods used in reviews.
The Specialized Register of the Cochrane Dementia and Cogni-
tive Improvement Group (CDCIG) was searched on 7 November
2007 for all years up to December 2005. This register contains
records from themajor healthcare databases,The Cochrane Library,
MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS, and
many ongoing trial databases and other grey literature sources.
The following search terms were used: ORT, PORT, ERT, HRT,
estrogen*, oestrogen* and progesterone*.
The Cochrane Library, MEDLINE, EMBASE, PsycINFO,
CINAHL and LILACS were searched separately on 7 November
2007 for records added to these databases after December 2005
to November 2007. The search terms used to identify relevant
controlled trials on Alzheimer’s disease and mild cognitive impair-
ment for the Group’s Specialized Register can be found in the
Group’s module on The Cochrane Library.These search terms were
combined with the following search terms and adapted for each
database, where appropriate: ORT, PORT, ERT, HRT, estrogen*,
oestrogen* and progesterone*.
On 7 November 2007, the CDCIG Specialized Register consisted
of records from the following databases:
Healthcare databases
• CENTRAL: (The Cochrane Library 2006, Issue 1);
• MEDLINE (1966 to 2006/07, week 5);
• EMBASE (1980 to 2006/07);
• PsycINFO (1887 to 2006/08, week 1);
• CINAHL (1982 to 2006/06);
• SIGLE (Grey Literature in Europe) (1980 to 2005/03);
• LILACS: Latin American and Caribbean Health Science
Literature (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/
online/?IsisScript=iah/iah.xis&base=LILACS&lang=i&form=F)
(last searched 29 August 2006);
Conference proceedings
• ISTP (http://portal.isiknowledge.com/portal.cgi) (Index to
Scientific and Technical Proceedings) (to 29 August 2006);
• INSIDE (BL database of Conference Proceedings and
Journals) (to June 2000);
Theses
• Index to Theses (formerly ASLIB) (http://www.theses.com/
) (UK and Ireland theses) (1716 to 11 August 2006);
• Australian Digital Theses Program (http://adt.caul.edu.au/
): (last update 24 March 2006);
• Canadian Theses and Dissertations (http://
www.collectionscanada.ca/thesescanada/index-e.html): 1989 to
28 August 2006);
• DATAD - Database of African Theses and Dissertations
(http://www.aau.org/datad/backgrd.htm);
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• Dissertation Abstract Online (USA) (http://
wwwlib.umi.com/dissertations/gateway) (1861 to 28 August
2006);
Ongoing trials
UK
• National Research Register (http://www.update-
software.com/projects/nrr/) (last searched issue 3/2006);
• ReFeR (http://www.refer.nhs.uk/ViewWebPage.asp?Page=
Home) (last searched 30 August 2006);
• Current Controlled trials: Meta Register of Controlled trials
(mRCT) (http://www.controlled-trials.com/) (last searched 30
August 2006)
• ISRCTN Register - trials registered with a unique identifier
• Action medical research
• Kings College London
• Laxdale Ltd
• Medical Research Council (UK)
• NHS Trusts Clinical Trials Register
• National Health Service Research and Development Health
Technology Assessment Programme (HTA)
• National Health Service Research and Development
Programme ’Time-Limited’ National Programmes
• National Health Service Research and Development
Regional Programmes
• The Wellcome Trust
• Stroke Trials Registry (http://www.strokecenter.org/trials/
index.aspx) (last searched 31 August 2006);
Netherlands
Nederlands Trial Register (http://www.trialregister.nl/trialreg/in-
dex.asp) (last searched 31 August 2006);
USA/International
• ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last
searched 31 August 2006) (contains all records from http://
clinicalstudies.info.nih.gov/);
• IPFMA Clinical trials Register: www.ifpma.org/
clinicaltrials.html. The Ongoing Trials database within this
Register searches http://www.controlled-trials.com/isrctn, http://
www.ClinicalTrials.gov and http://www.centerwatch.com/. The
ISRCTN register and Clinicaltrials.gov are searched separately.
Centerwatch is very difficult to search for our purposes and no
update searches have been done since 2003.
• The IFPMA Trial Results databases searches a wide variety
of sources among which are:
• http://www.astrazenecaclinicaltrials.com (seroquel, statins)
• http://www.centerwatch.com
• http://www.clinicalstudyresults.org
• http://clinicaltrials.gov
• http://www.controlled-trials.com
• http://ctr.gsk.co.uk
• http://www.lillytrials.com (zyprexa)
• http://www.roche-trials.com (anti-abeta antibody)
• http://www.organon.com
• http://www.novartisclinicaltrials.com (rivastigmine)
• http://www.bayerhealthcare.com
• http://trials.boehringer-ingelheim.com
• http://www.cmrinteract.com
• http://www.esteve.es
• http://www.clinicaltrials.jp
This part of the IPFMA database is searched and was last updated
on 4 September 2006;
• Lundbeck Clinical Trial Registry (http://
www.lundbecktrials.com) (last searched 15 August 2006);
• Forest Clinical trial Registry (http://
www.forestclinicaltrials.com/) (last searched 15 August 2006).
The search strategies used to identify relevant records fromMED-
LINE, EMBASE, PsycINFO, CINAHL and LILACS can be
found in the Group’s module on The Cochrane Library.
In April 2008 one of the authors (EH) did another MEDLINE
search update and also asked experts in the fieldwhether they knew
of any other ongoing trials. No new information could be added
on the basis of this search.
Data collection and analysis
Selection of studies
Abstracts of the references retrieved by the search were read by
two reviewers (EH and KY) in order to discard those that were
clearly not eligible for inclusion. The two reviewers studied the
full text of the remaining references and independently selected
studies for inclusion. Any disparity in the ensuing lists was resolved
by discussion with all reviewers in order to arrive at the final list of
included studies. One reviewer (EH) extracted the data from the
studies.
Quality assessment
Two reviewers assessed the quality of the studies according to the
Cochrane Collaboration guidelines which focus on the allocation
of treatment.
Category A (adequate) is where the report describes allocation of
treatment by: (i) some form of centralized randomized scheme,
such as having to provide details of an enrolled participant to
an office by phone to receive the treatment group allocation; (ii)
some form of randomization scheme controlled by a pharmacy;
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(iii) numbered or coded containers, such as in a pharmaceutical
trial in which capsules from identical-looking numbered bottles
are administrated sequentially to enrolled participants; (iv) an on-
site or coded computer system, given that the allocations were in a
locked, unreadable file that could be accessed only after inputting
the characteristics of an enrolled participant; or (v) if assignment
envelopes were used, the report should at least specify that they
were sequentially numbered, sealed, and opaque; (vi) other com-
binations of described elements of the process that provides assur-
ance of adequate concealment.
Category B (intermediate) is where the report describes allocation
of treatment by: (i) use of a “list” or “table” to allocate assignments;
(ii) use of “envelopes” or “sealed envelopes”; (iii) stating the study
as “randomized” without further detail.
Category C (inadequate) is where the report describes allocation of
treatment by: (i) alternation; (ii) reference to case record numbers,
dates of birth, day of week, or any other such approach; (iii) any
allocation procedure that is entirely transparent before assignment,
such as an open list of random numbers or assignments.
Empirical research has shown that lack of adequate allocation con-
cealment is associated with bias. Trials with unclear concealment
measures have been shown liable to yield more pronounced es-
timates of treatment effects than trials that have taken adequate
measures to conceal allocation schedules, but the bias is less pro-
nounced than in inadequately concealed trials (Chalmers 1983;
Schulz 1995).
Other aspects of the trial quality (methodology, statistics) were
noted for the discussion.
Data collection
Data for themeta-analyses were based on reported summary statis-
tics for each study.
To test cognitive change after treatment, the main outcome of in-
terest was the change from baseline to final assessment (mean dif-
ference in performance and SD of the mean difference in perfor-
mance). The baseline assessment was defined as the last available
assessment prior to randomization.
Data analysis
Meta-analyses were performed on the mean difference of the con-
tinuous psychometric test scores. The mean difference was calcu-
lated as the difference between post-treatment and baseline per-
formance. The standard deviation (SD) of this difference was cal-
culated as the square root of the variance of the baseline plus the
variance of the final assessment (assuming the covariance between
baseline and post-treatment values is 0) as advised in Cochrane
Collaboration guidelines unless data could be extracted. For stud-
ies that used the same treatment and the test outcome measure,
the weighted mean difference (WMD) was employed in the meta-
analyses. In these analyses a fixed-effect model was used if signif-
icant heterogeneity was not detected. If significant heterogeneity
was detected (using chi-square statistics), a possible explanation
was sought and both fixed- and random-effects models were re-
ported. When I2 >50%, a sensitivity analysis will be performed.
For studies that had employed different types of treatment or had
used different tests but measured the same construct (e.g. visual
memory), the standardized mean difference (SMD) was used with
either fixed-effect (when using the same test) or random-effects
models (when using a different test but measuring the same con-
struct).
The null hypothesis testedwas that, for any of the above outcomes,
treatment had no effect in comparison with placebo.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Nine double-blind placebo-controlled trials of postmenopausal
women with dementia were identified (see Characteristics of
included studies). However, in two (McDonald Caldwell 1952;
Honjo 1995) there was insufficient information about the ran-
domization procedure. In accordance with the Cochrane guide-
lines, these studies were excluded from analysis.
Subjects - screening and selection
The total number of participants randomized in the trials varied
from 14 to 120. In total, 351 women with dementia were included
(266 had completed the studies) with an average of 38 participants
per study. Drop-outs were described in four studies (but not in
Birge 1997 and Zhang 2006: although data provided by the inves-
tigator suggested no drop-outs): 21/176 of treated women (11%)
dropped out compared with 13/131 of placebo users (10%) for a
wide variety of reasons, mostly unrelated to the medication.
Most studies required very rigorous health screening (Mulnard
2000; Wang 2000; Henderson 2000; Asthana 1999; Asthana
2001). One study (Birge 1997) had less rigorous criteria (age < 70,
depression, non-AD dementia syndromes) and was a preliminary
analysis on 20 subjects which was published in a general article
on estrogen and hormonal replacement therapy. No follow-up
of these data (or a more detailed description of the study) has
been reported. Power analyses had been carried out by two studies
(Henderson 2000; Mulnard 2000) but were not mentioned in
the smaller studies (Asthana 1999; Asthana 2001, Birge 1997)
while Wang 2000 also failed to mention power analysis but would
(on the basis of the calculations of the first two studies) have had
sufficient numbers (n = 50).
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Subjects - dementia assessment
Most studies reported inclusion of people with dementia of the
Alzheimer’s type (DAT) or Alzheimer’s disease (AD), except in
Birge 1997 where patients had non-AD dementia syndromes.
Most studies employed the NINCDS/ADRDA criteria for prob-
able AD (but see Birge 1997, where no criteria were given) and
participants were in general considered to have mild to moderate
dementia (MMSE between 10 and 28).
Subjects - age and other confounding factors
The mean age of the women with AD was 75 years old, but some
studies had a large age-range (Mulnard 2000: range 56 to 91) and
had thus included early and late onset AD. In one study only early
age-onset AD patients (< 63 years of age) were included with mild
AD (Zhang 2006). Age, education and depressionwere usually not
controlled for in the analyses. Some studies included only women
whohad undergone natural menopause (Asthana 1999)while oth-
ers included mixed groups of surgically and naturally menopausal
women (e.g. Henderson 2000; Mulnard 2000; Asthana 2001) or
did not provide data on this.
Design
All studies used a parallel-group design. Duration of treatment
varied from eight weeks to 12 months, with an average of 4.4
months. We did not include the five week treatment time point
of Asthana 1999 as the authors pointed out that data may not
have been reliable, since two (of 12) participants had been tested
elsewhere.
Cognitive assessments
Not all studies used similar cognitive tests which made compari-
son difficult. One of the problems in the otherwise well designed
studies by Mulnard 2000 and Wang 2000 was, for instance, that
no common test of verbal memory was used. Verbal memory has
been thought likely to be most sensitive cognitive test to the effects
of estrogen (Hogervorst 2000).
Different types of treatment and estradiol levels
Four RCTs prescribed Premarin (CEE produced by Wyeth). Of
these, three used the 1.25 mg/day dosage (Henderson 2000;Wang
2000;Mulnard 2000) and two employed the lower dosage of 0.625
mg/day (Birge 1997; Mulnard 2000). Birge 1997 also added a
progestagen to the estrogen to prevent endometrial hyperplasia.
In one study (Zhang 2006) an Chinese estrogenic compound was
used (Beimeili) containing conjugated oestrogen, which was also
manufactured byWyeth-Ayerst in theUSA andwhichwas thought
to probably be similar to CEE. Unfortunately little information
could be found about this product which seems to be marketed
mainly in China. Two studies used transdermal estradiol (Asthana
1999; Asthana 2001). Compliance checks were done using pill
counts (Henderson 2000) or serum estrogen checks (Asthana
1999; Asthana 2001; Wang 2000; Mulnard 2000). Birge 1997
and Zhang 2006 gave no data on compliance checks.
Statistics
Some studies reported separate within-group comparisons for par-
ticipants in treatment and placebo groups (e.g. Birge 1997, Zhang
2006) which can result in chance accumulation and a risk of
the type I error. Five studies had performed ’completers’ analy-
ses (Birge 1997; Asthana 1999; Henderson 2000; Zhang 2006;
Mulnard 2000 but data not shown) and three had performed ’in-
tention-to-treat’ analyses (Mulnard 2000; Wang 2000; Asthana
2001).
Risk of bias in included studies
Three studies described their randomization procedures in detail
(Henderson 2000; Mulnard 2000 Asthana 2001) and received a
Cochrane quality rating of A. In these studies an external person
had performed the allocation. The other studies reported having
’randomly assigned treatments’ but did not describe the random-
ization procedures in detail, and in accordance with Cochrane
Collaboration standards received a quality rating of B. For two
studies no randomization procedure was reported and these were
not included in the analyses (Honjo 1989; McDonald Caldwell
1952).
Effects of interventions
Seven studies met inclusion criteria and had performed adequate
or intermediate allocation procedures. These studies had all been
published in peer-reviewed journals.
Global cognitive functioning
There was an overall positive effect for treatment on the MMSE
score after 1 to 2 months with the combined low and high dosages
(0.625 and 1.25 mg) CEE (WMD= 1.00, 95%CI = 0.06 to 1.94,
z = 2.09, P < 0.05, test for heterogeneity, P = 1.00). However, this
was the only test that showed a dosage effect: after two months
the low dosage, but not the 1.25 mg dosage, was significantly
better than placebo. The positive effect of the low dose onMMSE
performance did not persist after six and 12 months. In addition,
this effect is clinically irrelevant as there was only a one-point
difference on the MMSE between placebo and treatment. There
was also no evidence for an overall short-term effect of treatment
on theMMSE score (P =0.15), when theE2 transdermal treatment
was included in the analyses. The test for heterogeneity was not
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significant (P = 0.27) and there was no difference using SMD
with a fixed- or random-effects model, suggesting that combining
treatments did not violate prior assumptions of the analyses. The
effect of combined CEE treatment (low and high dosage) on the
MMSE score was not significant after 3, 6 and 12 months (P >
0.50). There was no evidence of an effect of treatment on the
ADAS-Cog after 1, 2, 4, 6 and 12 months of combined (0.625
mg + 1.25 mg) CEE treatment (P > 0.10). There was also no
evidence of an effect of treatment (E2 and 0.625 mg CEE) on
the BIMC after two and nine months (P > 0.30) and the tests for
heterogeneity were not significant (P = 0.35). There was an overall
effect of treatment on the HSD-R after four months of treatment
(WMD = 6.09, 95% CI = 0.98 to 11.20, z = 2.34, P < 0.05) in
the early onset AD cases (Zhang 2006) when conjugated estrogen
was compared to vitamin B1 treatment.
Memory tests
There was no significant effect of E2 transdermal or 1.25 mg CEE
treatment on the immediate ParagraphRecall test (P >0.15).How-
ever, controls had a slightly better performance after one month
than 1.25 mg CEE users on the delayed Paragraph Recall test
(WMD = -0.45, 95% CI = -0.79 to 10.11, z = 2.60, P < 0.01).
There was a trend for a reversal of this effect after four months (P
= 0.07). There was no evidence of a treatment effect on the BSRT
immediate recall after two months of E2 transdermal treatment
(P = 0.80). When these results were combined with that of an-
other study of this research group using a combined measure of
the immediate and delayed recall (derived from graphs), also no
overall effect of two months treatment with transdermal E2 was
detected (SMD random effects = 0.42, 95% CI = -0.29 to 1.12,
z = 1.16, P = 0.25). However, the BSRT cued delayed recall was
significantly better after two months of E2 transdermal than after
placebo (WMD = 6.50, 95% CI = 4.04 to 8.96, z = 5.19, P <
0.0001). Performance on the CERAD word list (P = 0.60) and on
the Paired Associate learning test (P = 0.16) were unchanged after
nine months of 0.625 mg CEE + MPA compared to placebo.
There was a trend (P = 0.07) for controls to have a better perfor-
mance on Digit Span forward after four to nine months of CEE
treatment (P = 0.09 for the four months treatment with 1.25 mg
CEE, and P = 0.50 for the nine months treatment with 0.625 mg
CEE +MPA). Differences in Category Fluency performance were
in the same direction, but were also not significantly different (P =
0.11) for controls compared with CEE treatment after combined
(0.625 + 1.25 mg) analyses after four (P = 0.82) and 12 months
(P = 0.08) of treatment. Heterogeneity tests were not significant
(Digit Span: P = 0.74 Fluency: P = 0.44) for these analyses.
No evidence for a treatment effect was detected on visual memory
tests, e.g. on the VRT after one and four months of 1.25 mg CEE
(P = 0.90); or on the VRT after two months of E2 transdermal (P
= 0.70); on the Rey Osterich visual memory test after two months
of transdermal E2 (P = 0.29) or on the Visual Span after four
months of 1.25mgCEE (P=0.12). Also, performance on the facial
recognition tests did not differ significantly between placebo and
combined (0.625 mg + 1.25 mg) CEE treatment after 12 months
(P = 0.40). The CASI long term memory test showed no evidence
(P > 0.30) of an effect with 1.25 mg CEE after two months. No
difference was detected in SMD analyses using random- or fixed-
effects models, and heterogeneity tests were also non-significant
in these analyses.
Language tests
There was no evidence of a treatment effect on the Boston Naming
test (P > 0.70) after four months of 1.25 mgCEE, or on the Token
test after one month of 1.25 mg CEE (P = 0.80), or after two
months of E2 transdermal (P = 0.50), or after four months of 1.25
mg CEE (P = 0.80).
Speed of information processing and concentration
tests
There was no evidence for an overall effect of placebo or treatment
on TMT-A performance. However, performance on the TMT-B
was better after one month of CEE (WMD = -40.90, 95% CI = -
79.29 to -2.51, z = 2.09, P < 0.05), which was no longer significant
after four and nine months of treatment (P > 0.40). There was no
evidence of a treatment or control effect on the Stroop Interference
test (P = 0.90), the DSST (P = 0.70), or the Letter Cancellation
test (P = 0.90). Only Finger Tapping was significantly faster after
12 months in controls (WMD = -3.90, 95% CI = -7.85 to 0.05,
z = 1.93, P < 0.05). Digit Span backward, as a measure of concen-
tration and controlled information processing, was significantly
better after four months of CEE (WMD = 0.67, 95% CI = -0.01
to 1.34, z = 1.94, P < 0.05) but not after one month of CEE (P =
0.12) or after nine months of CEE + MPA (P = 1.00).
Clinical impression of change, dementia severity and
depression scales
Both the CGIC and CIBIC showed no evidence of a treatment
effect (P = 0.40). However, theCDR scores revealed that clinicians
in general rated dementia severity to be less in participants taking
placebo than in those on active treatment after 1.5 to 12 months
(overallWMD = 0.35, 95% CI = 0.01 to 0.69, z = 1.99, P < 0.05).
The Hamilton Depression rating scale did not show any evidence
of a positive or negative effect of treatment (P = 1.00) after 3 or
12 months.
The heterogeneity test was not significant in any of the analyses,
which could indicate that the results from studies were compara-
ble and that the pooling of the data was valid. Using SMD with
random-effects models when a significant effect was found also
did not alter results.
In sum, the following effects were seen:
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(i) There was a significant positive effect of a low dose of CEE
up to two months when compared to placebo (Mulnard 2000).
The higher dose of CEE and E2 did not show positive effects of
treatment (Mulnard 2000, Wang 2000; Asthana 1999; Asthana
2001)
(ii) After twomonths positive effects of low dose E2 on the delayed
recall of the BSRT (Asthana 1999) was shown (but the reverse
was found after one month of CEE on the delayed paragraph
recall, which was better for controls). However, there was a trend
for this to reverse again at four months within the same study by
Henderson 2000. No effects were found on immediate recall or on
other word learning lists, visual memory tests or language tests.
(iii) After four months positive effects were seen after CEE (high
dose) on Digit Span backward and the TMT-B test, but a reverse
trend was seen in the same study (Henderson 2000) after four
months for the Digit Span forward test. No effects were seen on
other complex speeded tests.
(iv) After four months also a positive effect was seen of high dose
CEE on the HDS-R test (Zhang 2006) but this had not been
significant between groups using the same test in another (not
included) study (Honjo 1995) after a similar treatment duration
with CEE and MPA.
(v) After 12 months, controls performed better than CEE on the
Finger Tapping and the CDR, with a similar trend for the verbal
Fluency test.
Using the inverse* Bonferroni rule for multiple comparisons of the
separate analyses involving the same test used in different studies
(including those which had been performed, but for which we had
no data to include in the analyses), most HRT and ERT effects
disappeared:
- The effects of CEE on the MMSE (P = 0.04 x 4) and TMT-B
(P = 0.04 x 5) within one month of treatment, and on the Digit
Span backward (P = 0.04 x 2) after four months of treatment did
not remain.
-The effect of E2 transdermal treatment on theBSRTcueddelayed
recall after two months did remain (P = 0.0001 x 2) and that of
the HDS-R after four months of CEE in participants with early
onset dementia (P = 0.02 x1).
- The findings of controls having a better performance than ERT
users also remained, even after inverse Bonferroni corrections
(Paragraph Delayed Recall after 1 month, P = 0.009 x 3; Finger
Tapping after 12 months, P = 0.05 and CDR after 12 months, P
= 0.01 x 2).
*the P value for a test becomes kP. For example, an uncorrected
significance value of 0.02, where there are five tests, would become
5(0.02) or 0.1
D I S C U S S I O N
This review found no overall positive effect of HRT or ERT in
maintaining cognitive function in AD. There was a limited pos-
itive effect (in time and effect size) on a test of global cognitive
functioning, theMMSE. This effect was only significant after one
to two months (but not after 3, 6, and 12 months) of a low dosage
(0.625 mg) CEE treatment and disappeared after correction for
multiple testing. In addition, this effect was small and clinically
irrelevant (difference of 1 point on average). Others also reported
not finding effects of two months transdermal estradiol (E2) treat-
ment on the MMSE (Asthana 2001) but as we had no data avail-
able, these results could not be included in themeta-analyses. Sim-
ilarly, the positive time-limited effect of CEE on two tests which
measured concentration and executive function (the TMT-B af-
ter one month CEE and Digit Span backward after four months
CEE) disappeared after statistical correction for multiple testing.
Only the effect of two months of a transdermal E2 treatment on
cued delayed recall of a word list (BSRT Asthana 1999) remained
after correction. However, a combined score (derived from graphs
in the article) showed no effect in another study using the same
treatment for the same period of time, but with a higher dose.
No effects of HRT or ERT were seen on the delayed paragraph
recall or on immediate verbal recall in general (of a paragraph or
of a word list), on visual memory, language or on most speeded
tests. There were no positive effects on the clinical rating scales or
on mood. In several instances, placebo gave better performance
than treatment, for instance on the Paragraph Delayed Recall af-
ter one month of CEE (although there was a trend for this to re-
verse after four months) and on Finger Tapping after 12 months.
While it could be suggested that cognitive tests may not reflect
clinical change, dementia severity was also judged to be less severe
in controls than in cases who had been treated with CEE for 12
months. One study (Zhang 2006) reported an effect of a conju-
gated estrogen on a global test (HSD-R) after four months against
vitamin B1 (thiamine). Another Cochrane review could not re-
port positive effects in RCTs investigating the effects of thiamine
on cognitive function in AD (Rodríguez-Martín 2001), but it is
not entirely clear how to interpret these results without a perhaps
more appropriate placebo.
The following aspects need perhaps to be taken into account when
reviewing the results of our meta-analyses.
- Size of studies and error introduced through recalculation of the
SD of the mean difference
The initial study (Asthana 1999) that maintained its significant
effect of ERT was small (n = 12) and treatment with transdermal
E2 was conducted for only a short period of time (two months).
The later study (Asthana 2001) with a higher dose of the same
treatment regimen (which also claimed similar effects) could not
be replicated when data were extracted from graphs. A significant
limitation of our analyses is that data needed to be extracted from
graphs whichmay not have validly reflected the actual effect found
(e.g. incorrect SE or introduction of error when extracting data
using rulers). In addition, calculating the SD of the mean differ-
ence from extracted data was in our own analyses (using data of
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other treatment studies to compare actual and calculated SD of
the mean difference) shown to sometimes overestimate the SD by
a factor of two, especially in the smaller studies (n = 10-15). Most
of the data used in the present review were judged by the original
authors in peer-reviewed papers to show significant effects, which
could, however, often not be replicated in our analyses of the in-
dividual studies. Instead many trends emerged which suggested a
possible time-dependent effect, with positive effects seen after 1-2
months of treatments on some tests and negative effects seen after
12 months of estrogen treatment (see also Yesufu 2007)
- Type of cognitive test
Our earlier meta-analyses of the effects of estrogen treatment in
healthy women (Yesufu 2007) found effects of E2 (intramuscu-
lar injections, but not of the transdermal E2 treatment) on verbal
memory (in particular on one test, the Paired Associate learning
test) and on some executive functions which had all been carried
out by one research group. In the current review, the Paired As-
sociate test had only been used in one study (Birge 1997). While
effects seemed in favour of HRT, significance was not reached. As
this was also a small study, it is difficult to assess whether the lack
of effects could be attributed to the lack of power. Alternatively,
these types of tests could be too complicated for AD cases. In this
regard, cued recall, which is a much easier memory test, did show
an effect of E2 treatment in the small AD study (Asthana 1999)
for a limited duration of time. Othermore complex cognitive tests
(executive function) were shown to be affected by ERT both in
women with and those without dementia, but again only for a
limited period of time (< five months). It should be noted that
several studies using similar tests in our analyses failed to replicate
the significant short duration positive effects of ERT that had been
reported by the authors.
- Type of treatment (estrogen, duration and dosage)
While at present it is unclear whether the type of estrogen could
account for differences in the results found, we can conclude that
CEE does not have positive effects in women with AD after a
longer period of treatment (> five months). This is in in line with
the Chinese study (Zhang 2006) using a conjugated estrogen (de-
veloped by the same company who produces the CEE, Wyeth)
which reported positive effects of ERT after four months when
compared to vitamin B1.
It is unclear what the longer-term effects of E2 treatment would
be. A single-blind study for 18 months in institutionalized women
by McDonald Caldwell 1952 (in Hogervorst 2000, which could
not be included in this analyses) suggested that the effects of in-
tramuscular injections of 2 mg of E2/week also (similar to CEE)
declined after 12 months on several cognitive tests.
Another important question has been whether adding a progesta-
gen could alter effects (Honjo 1995). This has often been assumed,
as animal studies have shown that progestagens can counteract
several of the actions of estrogens on monoaminergic neurotrans-
mitter systems and possibly on the vascular system (Hogervorst
2000). The one study (Birge 1997) of a longer duration, which
added a progestagen to CEE, showed a slightly better performance
on the Digit Span forward and the CIBIC compared with the
studies that only used CEE (in a higher dosage).
Matters are complicated as the study which used the progestagen
(Birge 1997) also used a lower dosage of CEE than the other stud-
ies (Wang 2000; Henderson 2000). While in another study the
low dosage of CEE was seen to have positive effects on theMMSE
for a short period, after 12 months the 0.625 mg dosage of CEE
actually tended to lead to worse performance than placebo, while
the higher 1.25 mg regimen was associated with better interme-
diate performance (Mulnard 2000). It is at present thus unclear
(but also unlikely) whether the dosage of CEE or the addition of
a progestagen could alter treatment effects.
It has been suggested by Toran-Allerand 2000 that continuous
longer-term treatment with estrogens could result in a down-reg-
ulation of estrogen receptors in the brain. On some tests a posi-
tive effect was indeed seen for a limited duration of time. These
positive effects usually disappeared after five months and in some
cases even reversed. Adding a progestagen could potentially reverse
down-regulation of receptors. However, the study by Birge 1997
did not seem to show a overall larger effect in comparison with
the study by Mulnard where no progestagen was added.
- Participants (age at onset of AD and at testing, education,
menopausal status and other potential confounds)
The largest and longest study had a wide age range (Mulnard
2000: range 56 to 91). Age usually explains much of the variance
in cognitive tests and could have over-ridden the small effects of
treatment. The age range in the Mulnard 2000 study also indi-
cated that both participants with early- and late-onset AD had
been enrolled. This was also probably the case for the study by
Wang 2000. Early- and late-onset AD are thought to differ in
pathogenesis, and this could possibly have interacted with ERT
or HRT. Whether HRT or ERT could have an effect in women
with early-onset AD was investigated in the study by Zhang 2006
which intrigingly reported overall positive effects of treatment.
This finding could support the ’window of opportunity’ theory
which states that hormones need to be given close to the natural
age of menopause (around 50 years of age) to have a positive effect
on the brain and which is substantiated by animal and human
observational studies (Henderson 2008; Gibbs 2008).
Education and depression were often not controlled for, and an
earlier review (Hogervorst 2000) suggested that women with low
levels of education (who are additionally at risk for AD)may profit
most from HRT or ERT. The MMSE in general had a wide range
(10 to 28) indicating a wide variety of dementia severity in partici-
pants. Women with very mild dementia or mild cognitive impair-
ment would be an important group to study as theymay havemore
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potential for benefit. Lastly, the current review did not include
studies which selectively investigated women resident in nursing
homes, and conclusions are therefore restricted to a largely com-
munity-dwelling population.
In sum, from our meta-analyses it has become clear that in the
longer term (> two months) that any (if at all) potential positive
effects of estrogens on the brain seem to reverse. Overall data do
not suggest that treatment with HRT or ERT for longer than a
few months is recommended to maintain cognitive function in
postmenopausal women with or without dementia.
The large prospective randomized placebo-controlled studies
in the USA (Women’s Health Initiative, WHI; PREPARE)
(Schumaker 1998) and the UK (Women’s International Study
of long Duration estrogen after Menopause, WISDOM) were
abruptly stopped after the WHI found increased risks for breast
cancer and cardiovascular disease. In addition, a doubled risk for
dementia was reported in women who had been randomized to
Premarin (CEE) in combination with MPA treatment (Shumaker
2003) and a non significant effect for CEE alone was found in the
same direction (Shumaker 2004). This led to a substantial drop
in HRT and ERT use, although data suggested that many women
resumed taking (different) estrogens after a couple of months
(Wegienka 2006). The majority of observational studies suggested
that the risk for AD is decreasedwith the use ofHRTor ERT (Yaffe
1998a; Hogervorst 2000). Since Premarin is the most widely pre-
scribed drug, it was believed that it had protective effects against
the development of AD. Part of that effect may be due to the
’healthy user bias’ (see introduction), but this does not take into
account the overwhelming evidence for estrogen’s protective effect
on the brain as is still reported in animal and cell-culture stud-
ies. Interestingly, also before WHI results were published, many
women did not seem to use HRT for a long time (the majority <
one year) to treat menopausal symptoms (Wegienka 2006).
Current evidence indicates that only short-term treatment with
HRT is advisable; longer-term treatments should be avoided.
Genotypes associated with sex steroid metabolism and AD should
be investigated to see whether somewomen aremore at risk for this
than other women (Hogervorst 2007). Intermittent treatments
could be pursued as an alternative treatment option in conjunc-
tion with this (Al-Azzawi 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, the long-term use of HRT or ERT for cognitive im-
provement or maintenance in women with Alzheimer’s disease is
not indicated.
Implications for research
Novel treatment strategies should be investigated for longer term
treatment of cognitive dysfunction in AD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asthana 1999
Methods Design:
randomized, placebo- controlled, double blind
parallel groups
8 weeks
Participants Country: U.S.A.
n=14 (12 completers) probable AD NINCDS/ADRDA, mild-moderate dementia (MMSE: 17-25), not institution-
alised. Aged 79 (SD 8, 77-85 yrs). Exclusion criteria: medical, neurological or psychiatric disease. HRT or cognition
enhancer use last for the 2 months. Natural menopause ? (all underwent pap smears)
Interventions 1. E2 transdermal 0.05 mg
2. Placebo
Outcomes General (MMSE, BIMC)
Memory: (BSRT, VRT, Paragraph recall)
Speed (Stroop, TMT), Language: Fluency (letter), Token test
Notes HRT > placebo: on BSRT, Stroop (trends for VRT & Token test) 4/9 test
Adverse events:
1 drop-out due to skin irritations
Asthana 2001
Methods Design:
randomized, placebo- controlled, double blind
parallel groups
8 weeks
Participants Country: U.S.A.
n=20 (20 completers) probable AD NINCDS/ADRDA, mild-moderate dementia (MMSE: 10-29), Aged 80 (SD 7,
61-90 yrs). Exclusion criteria: medical, neurological or psychiatric disease. Psychoactive medication, cholinesterase
inhibitors or HRT use last for the 2 months. Mixed menopause (all underwent pap smears)
Interventions 1. E2 (17-beta transdermal 0.10 mg
2. Placebo
Outcomes General (MMSE, BIMC)
Memory: (BSRT, Paragraph recall, Rey Osterich Visual memory test, Visual Paired Associates, Oculomotor Delayed
response), Boston Namin Test (semantic)
Speed (Stroop, TMT), Treisman Visual Search Other: CIBIC, IADL, BPRS, PSMS
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Asthana 2001 (Continued)
Notes HRT>placebo: attention: Stroop, memory: BSRT, Rey Visual Memory, BNT)
Adverse events: breast tenderness (2 ERT), skin irritation patch (3 on ERT). No bleeding or spotting, no deep vein
thrombosis, pulmonary embolism
Birge 1997
Methods Design:
randomized,placebo- controlled, double-blind
parallel groups
9 months
Participants Country: U.S.A.
n=20 DAT (DSM?), mild dementia (CDRS <2)
Aged 77 (SD 6, 67-86). Exclusion criteria: Depression (GDS >5), age < 70, Other types of dementia syndromes
Interventions 1. CEE oral 0.625 mg/day + MPA 5 mg for 15 days every 3rd mth
2. Placebo
Outcomes General (BIMC)
Memory (CERAD word list, Paired Associates, Digit Span), Speed (TMT), Other (Clock drawing)
Notes HRT >placebo: on Paired associate, Placebo > HRT: on BMIC, Digit Span 1/6 tests
Henderson 2000
Methods Design:
randomised, placebo- controlled, double-blind
parallel groups
4 months
Participants Country: U.S.A.
n=42 (36 completers) probable AD (NINCDS), mild dementia (MMSE 10-26). Aged 78 (SD 1). Mix natural and
surgical menopause. Exclusion criteria: Contra- indications for HRT use, no use HRT or cognition enhancers last 3
months
Interventions 1. CEE oral 1.25 mg/day
2. Placebo
Outcomes General (ADAS-Cog, BIMC)
Memory: (Paragraph recall, VRT, Digit Span), Speed: (TMT) Language (Naming, Token test)
Notes HRT > placebo on TMT-B (wk 4), Placebo > HRT on VRT (wk 16), Paragraph recall + Digit span (wk 4), trend
for reverse for both at wk 16
1/8 tests
Adverse events:
3 vaginal spotting
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Honjo 1995
Methods Design: placebo- controll ed, double-blind
parallel groups, 7 weeks
Participants Country: Japan
n=14 AD (criteria?) (13 completers), mild dementia (MMSE: 18 SD 6). Aged 84 (SD 5). Natural menopause
(bleeding). No exclusion criteria ?
Interventions 1. CEE oral 1.25 mg /day for 3 wks
+ MPA 2.5 mg/day for last 3 weeks
2. Placebo
Outcomes General (MMSE and Japanese dementia scales: NSD HDS)
Notes HRT: all improved > baseline, 3/3 test. No between groups effect.
Adverse events:
11 vaginal bleeding
McDonald Caldwell 1952
Methods Design:
placebo- controlled
double-blind
parallel groups
6 months
Participants Country: U.S.A.
n=30 nursing home residents, probably with dementia. Aged 75 years (54-88). Natural menopause. Exclusion criteria:
inability to communicate, evidence of neoplasm
Interventions 1. E2 i.m., 1 mg 3x/wk for 6 wks, then 2 mg/ wk +P 5-10 mg for 1-3 days/mth
2. Placebo
Outcomes General (IQ)
Memory (WMS: Paragraph recall, Paired Associates,VRT, Digit Span)
Speed (DSST, Stroop)
Notes HRT> placebo: on total memory (Paragraph recall, Paired Associates). No effect Digit Span, DSST, Stroop 2/5
Mulnard 2000
Methods Design:
randomized, placebo- controlled, double-blind
parallel groups, 12 months
Participants Country: U.S.A., multi-centre trial
n= 120 probable AD NINCDS/ADRDA, (97 completers), mild- moderate dementia (MMSE: 12-28). Aged 56-
91. Hysterectomized, mix natural and surgical menopause. Exclusion criteria: age < 60, depression, CVD, types of
medication (no use HRT last 3 months, stabile use donazepil allowed)
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Mulnard 2000 (Continued)
Interventions 1. CEE oral 0.625 mg/day
2. CEE 1.25 oral mg/day
2. Placebo
Outcomes General (MMSE, ADAS-Cog)
Memory (new dot test, face recognition)
Speed: (TMT, letter cancellation, finger tapping, DSST) Language (Fluency)
Notes HRT> placebo MMSE after 2 months, after 12 month worse
(Fluency, finger tapping) 1/9 tests
Adverse events: 4 had deep vein thrombosis, 2 vaginal bleeding
Wang 2000
Methods Design:
randomised, placebo- controlled, double-blind
parallel groups,
3 months
Participants Country: Taiwan
n=50 prob AD NINCDS/ADRDA, (47completers) mild- moderate dementia (MMSE: 10-26). Aged 72 (SD 9).
Naturalmenopause ? (all had pap smears). Exclusion criteria: diabetes, cancer, hypertension, active disease, depression,
use cognition enhancers last 3 months, use HRT last month
Interventions 1. CEE oral 1.25 mg/day
2. Placebo
Outcomes General: (MMSE-CE, CASI)
Notes no effect HRT over placebo 0/2 tests. Adverse events: 11 had vaginal bleeding
Zhang 2006
Methods Design:
randomised, double-blind, parallel groups
4 months
Participants Country: China
n=41 mild AD (DSM-IV)
Aged 47-62 (55 +/-0.4) years
All menopause before age 65
Exclusion:dementia due to ’vessel, infection, toxication, metabolism, liver/kidney dysfunction or depression. All gave
informed consent and had CT/MRI
Interventions 1. Beimeili (conjugated estrogen, Wyeth, USA) oral/1.25 mg /day
2. vit B1 20 mg 3x/day as Placebo
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Zhang 2006 (Continued)
Outcomes General Hasegawa Dementia Scale-R (HDS-R)
ADL
Notes HRT > vitamin B1 after 4 months on HDS-R and ADL
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Fillit 1986 not RCT
Fillit 1994 not RCT
Honjo 1989 Not RCT
Kantor 1973 Only used hospital adjustment scores and no cognitive tests
Ohkura 1994a Not RCT
Ohkura 1994b Not RCT
Ohkura 1995 Not RCT
Rigaud 2003 Comparison between HRT + rivastigmine vs. placebo + rivastigmine: HRT did not give further improvement over
rivastigmine alone
Yoon 2003 Open label
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D A T A A N D A N A L Y S E S
Comparison 1. Global cognitive functioning
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MMSE after 1,5 -2 months CEE
(0.625 + 1.25 mg combined)
or placebo
2 163 Mean Difference (IV, Fixed, 95% CI) 1.0 [0.06, 1.94]
2 MMSE after 2 months with
0.625 mg CEE or placebo
1 81 Mean Difference (IV, Fixed, 95% CI) 1.28 [0.26, 2.30]
3 MMSE after 1-2 months with
1.25 mg CEE or placebo
2 125 Mean Difference (IV, Fixed, 95% CI) 0.65 [-0.20, 1.50]
4 MMSE after 2 months ERT or
placebo
2 128 Std. Mean Difference (IV, Fixed, 95% CI) 0.28 [-0.10, 0.65]
4.1 After E2 (0.05 mg
transdermal) or placebo
(Asthana 1999)
1 12 Std. Mean Difference (IV, Fixed, 95% CI) -0.33 [-1.47, 0.82]
4.2 After CEE (0.625 mg +
1.25 mg combined) (Mulnard
2000)
1 116 Std. Mean Difference (IV, Fixed, 95% CI) 0.35 [-0.05, 0.75]
5 MMSE after 3-6 months CEE
(0.625 + 1.25 mg) or placebo
2 144 Mean Difference (IV, Fixed, 95% CI) 0.41 [-0.75, 1.57]
6 MMSE after 12 months with
(0.625 mg + 1.25 mg) CEE or
placebo
1 97 Mean Difference (IV, Fixed, 95% CI) 0.40 [-1.28, 2.08]
7 ADAS-Cog after 1-2 months
with (0.625 mg + 1.25 mg)
CEE or placebo
2 152 Mean Difference (IV, Fixed, 95% CI) 0.38 [-1.20, 1.96]
8 ADAS-Cog after 4-6 months
with (0.625 mg + 1.25 mg)
CEE or placebo
2 131 Mean Difference (IV, Fixed, 95% CI) -0.40 [-2.52, 1.73]
9 ADAS-Cog after 12 months
with (0.625 mg + 1.25 mg)
CEE or placebo
1 97 Mean Difference (IV, Fixed, 95% CI) 0.00 [-4.41, 0.41]
10 ADAS-Cog after 12 months
with 0.625 mg CEE or placebo
1 67 Mean Difference (IV, Fixed, 95% CI) -2.70 [-6.01, 0.61]
11 ADAS-Cog after 12 months
with 1.25 mg CEE or placebo
1 62 Mean Difference (IV, Fixed, 95% CI) -1.20 [-3.73, 1.33]
12 Blessed (BIMC) after 2-9
months ERT or placebo
2 30 Mean Difference (IV, Fixed, 95% CI) -3.55 [-9.71, 2.60]
12.1 after 2 months E2 (0.05
mg transdermal) or placebo
1 12 Mean Difference (IV, Fixed, 95% CI) 0.20 [-9.34, 9.74]
12.2 after 9 months 0.625 mg
CEE +MPA or placebo
1 18 Mean Difference (IV, Fixed, 95% CI) -6.24 [-14.31, 1.83]
13 HDS-R after 16 weeks
(estrogen) or vitamin B1 as
placebo
1 41 Mean Difference (IV, Fixed, 95% CI) 6.09 [0.98, 11.20]
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Comparison 2. Memory tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Paragraph recall (immediate +
delayed) after 2 months with
E2 transdermal or placebo
1 12 Mean Difference (IV, Fixed, 95% CI) -1.20 [-6.98, 4.58]
2 Paragraph recall (immediate)
after 1 month with 1.25 mg
CEE or placebo
1 39 Mean Difference (IV, Fixed, 95% CI) 0.52 [-0.99, 2.03]
3 Paragraph recall (delayed) after 1
month with 1.25 mg CEE or
placebo
1 40 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.79, -0.11]
4 Paragraph recall immediate after
4 months with 1.25 mg CEE
or placebo
1 35 Mean Difference (IV, Fixed, 95% CI) 1.58 [-0.57, 3.73]
5 Paragraph recall (delayed) after 4
months with 1.25 mg CEE or
placebo
1 34 Mean Difference (IV, Fixed, 95% CI) 0.83 [-0.06, 1.72]
6 Busche Selective Reminding
(delayed recall) after 2 months
with E2 transdermal or place
1 12 Mean Difference (IV, Fixed, 95% CI) 6.5 [4.04, 8.96]
6.1 BSRT delayed recall score
(1999)
1 12 Mean Difference (IV, Fixed, 95% CI) 6.5 [4.04, 8.96]
7 Buschke Selective Reminding
(Ir, IR+DR) after 2 months
with E2 transdermal or placebo
2 32 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.29, 1.12]
7.1 Sub-category 2 32 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.29, 1.12]
8 CERAD word list after 9 months
with 0.625 mg CEE + MPA or
placebo
1 16 Mean Difference (IV, Fixed, 95% CI) -0.67 [-2.87, 1.53]
9 Paired Associate word learning
after 9 months with 0.625 mg
CEE + MPA or placebo
1 20 Mean Difference (IV, Fixed, 95% CI) 2.43 [-0.94, 5.80]
10 Verbal Fluency tests (semantic
memory)
2 133 Std. Mean Difference (IV, Fixed, 95% CI) -0.29 [-0.65, 0.07]
10.1 Category fluency after 4
months with 1.25 mg CEE or
placebo
1 36 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.73, 0.58]
10.2 Category Fluency after
12 months with 0.625 + 1.25
mg CEE or placebo
1 97 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.81, 0.05]
11 Visual Retention Test
(WMS) after 2 months of E2
transdermal or placebo
1 12 Mean Difference (IV, Fixed, 95% CI) 5.0 [-17.59, 27.59]
11.1 VRT (immediate +
delayed) after 2 months with
E2 transdermal and placebo
1 12 Mean Difference (IV, Fixed, 95% CI) 5.0 [-17.59, 27.59]
12 Visual Retention Test (WMS)
after 1.25 mg CEE or placebo
1 143 Mean Difference (IV, Fixed, 95% CI) -0.04 [-1.08, 1.00]
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12.1 VRT (immediate) after 1
month with 1.25 mg CEE or
placebo
1 39 Mean Difference (IV, Fixed, 95% CI) 1.59 [-2.39, 5.57]
12.2 VRT (delayed) after 1
month with 1.25 mg CEE or
placebo
1 33 Mean Difference (IV, Fixed, 95% CI) 0.14 [-1.34, 1.62]
12.3 VRT (immediate) after 4
months with 1.25 mg CEE or
placebo
1 35 Mean Difference (IV, Fixed, 95% CI) -0.09 [-4.68, 4.50]
12.4 VRT (delayed) after 4
months with 1.25 mg CEE or
placebo
1 36 Mean Difference (IV, Fixed, 95% CI) -0.55 [-2.23, 1.13]
13 Visual span foward after 4
months of 1.25 mg CEE or
placebo
1 36 Mean Difference (IV, Fixed, 95% CI) -0.72 [-1.64, 0.20]
14 Face recognition after 12
months of 0.625 + 1.25 mg
CEE or placebo
1 97 Mean Difference (IV, Fixed, 95% CI) -2.00 [-12.49, 4.49]
15 Digit span forward (STM and
concentration)
2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-1.08, 0.04]
15.1 Digit Span foward after
4 months with 1.25 mg CEE +
MPA or placebo
1 36 Std. Mean Difference (IV, Fixed, 95% CI) -0.58 [-1.25, 0.09]
15.2 Digit Span forward
after 9 months with 0.625 mg
CEE+MPA or placebo
1 15 Std. Mean Difference (IV, Fixed, 95% CI) -0.37 [-1.40, 0.65]
16 Other memory tests 2 67 Std. Mean Difference (IV, Random, 95% CI) 0.36 [-0.12, 0.85]
16.1 CASI LTM after 1,5
week with 1.25 mg CEE or
placebo
1 47 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.26, 0.89]
16.2 Visual memory
adaptation Rey test Immediate
recall after 2 months of
transdemral E2 or placebo
1 20 Std. Mean Difference (IV, Random, 95% CI) 0.48 [-0.41, 1.37]
Comparison 3. Language tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Token test after 1-2 months of
HRT or placebo
2 45 Std. Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.54, 0.63]
1.1 Token test after 1 months
with 1.25 mg CEE and placebo
1 33 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.77, 0.60]
1.2 Token test after 2 months
with E2 transdermal or placebo
1 12 Std. Mean Difference (IV, Fixed, 95% CI) 0.41 [-0.74, 1.56]
2 Token test after 4 months with
1.25 mg CEE or placebo
1 31 Mean Difference (IV, Fixed, 95% CI) 0.44 [-3.39, 4.27]
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3 Boston Naming Test after 4
months with 1.25 mg CEE or
placebo
1 36 Mean Difference (IV, Fixed, 95% CI) 0.78 [-2.93, 4.49]
Comparison 4. Speed of information processing and concentration tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 TMT-A after 1 month with 1.25
mg CEE or placebo
1 40 Mean Difference (IV, Fixed, 95% CI) -31.52 [-70.40, 7.
36]
2 TMT-A after > 2 months HRT
or placebo
4 165 Std. Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.39, 0.24]
2.1 TMT-A (time) after 2
months with E2 transdermal or
placebo
1 12 Std. Mean Difference (IV, Fixed, 95% CI) -0.22 [-1.36, 0.91]
2.2 TMT-A (time) after 4-12
months with (0.625 mg + 1.25
mg) CEE or placebo
2 133 Std. Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.37, 0.34]
2.3 TMT-A (lines/sec,
reversed) after 9 months with
0.625 mg CEE + MPA or
placebo
1 20 Std. Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.29, 0.49]
3 TMT-B after 1 month with
CEE or placebo
1 36 Mean Difference (IV, Fixed, 95% CI) -40.9 [-79.29, -2.51]
4 TMT-B after > 2 months 2 56 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.74, 0.32]
4.1 TMT-B after 4 months
with 1.25 mg CEE or placebo
1 36 Std. Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.98, 0.33]
4.2 TMT-B after 9 months
with 0.625 mg CEE + MPA or
placebo
1 20 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Stroop after 2 months with E2
transdermal or placebo
2 32 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.90, 0.49]
6 DSST after 12 months with
(0.625 mg + 1.25 mg) CEE or
placebo
1 97 Mean Difference (IV, Fixed, 95% CI) 0.5 [-2.51, 3.51]
7 Letter Cancellation test after 12
months with (0.625 mg + 1.25
mg) CEE or placebo
1 97 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.74, 2.54]
8 Finger tapping after 12 months
with (0.625 mg + 1.25 mg)
CEE or placebo
1 97 Mean Difference (IV, Fixed, 95% CI) -3.9 [-7.85, 0.05]
9 Digit Span backwards after 1
month of 1.25 mg CEE or
placebo
1 40 Mean Difference (IV, Fixed, 95% CI) 0.76 [-0.37, 1.89]
10 Digit Span backwards after > 4
months of CEE
2 54 Std. Mean Difference (IV, Fixed, 95% CI) 0.43 [-0.12, 0.97]
10.1 Digit span after 4 months
with 1.25 mg CEE or placebo
1 36 Std. Mean Difference (IV, Fixed, 95% CI) 0.67 [-0.01, 1.34]
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10.2 Digit Span after 9
months with 0.625 mg CEE +
MPA or placebo
1 18 Std. Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.94, 0.90]
Comparison 5. Clinical impressions of change scales
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CGIC (score of 4=no change
from baseline, higher=worse)
2 135 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.14, 0.34]
1.1 after 1 month with 1.25
mg CEE or placebo
1 38 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.18, 0.38]
1.2 After 12 months with
(0.625 mg + 1.25 mg) CEE or
placebo
1 97 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.34, 0.54]
2 CDR (higher=worse) 2 144 Std. Mean Difference (IV, Fixed, 95% CI) 0.35 [0.01, 0.69]
2.1 After 1,5 months with
1.25 mg CEE or placebo
1 47 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 After 12 months with
(0.625 mg + 1.25 mg) CEE or
placebo
1 97 Std. Mean Difference (IV, Fixed, 95% CI) 0.55 [0.12, 0.98]
3 CIBIC 2 64 Std. Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.73, 0.27]
3.1 After 1,5 month with 1.25
mg CEE or placebo
1 47 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 After 9 months with 0.625
mg CEE + MPA or placebo
1 17 Std. Mean Difference (IV, Fixed, 95% CI) -0.99 [-2.01, 0.04]
Comparison 6. Depression scales
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HDRS 2 144 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.90, 0.96]
1.1 After 3 months with 1.25
mg CEE or placebo
1 47 Mean Difference (IV, Fixed, 95% CI) -1.6 [-4.64, 1.44]
1.2 After 12 months with
(0.625 mg + 1.25 mg) CEE or
placebo
1 97 Mean Difference (IV, Fixed, 95% CI) 0.2 [-0.78, 1.18]
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Analysis 1.1. Comparison 1 Global cognitive functioning, Outcome 1 MMSE after 1,5 -2 months CEE (0.625
+ 1.25 mg combined) or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 1 MMSE after 1,5 -2 months CEE (0.625 + 1.25 mg combined) or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 81 -0.7 (2.7) 35 -1.7 (3.1) 63.0 % 1.00 [ -0.18, 2.18 ]
Wang 2000 24 0.3 (2.8) 23 -0.7 (2.6) 37.0 % 1.00 [ -0.54, 2.54 ]
Total (95% CI) 105 58 100.0 % 1.00 [ 0.06, 1.94 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Global cognitive functioning, Outcome 2 MMSE after 2 months with 0.625 mg
CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 2 MMSE after 2 months with 0.625 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 42 -0.36 (2.1) 39 -1.64 (2.56) 100.0 % 1.28 [ 0.26, 2.30 ]
Total (95% CI) 42 39 100.0 % 1.28 [ 0.26, 2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Global cognitive functioning, Outcome 3 MMSE after 1-2 months with 1.25 mg
CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 3 MMSE after 1-2 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 39 -1 (2.01) 39 -1.5 (2.56) 69.6 % 0.50 [ -0.52, 1.52 ]
Wang 2000 24 0.3 (2.8) 23 -0.7 (2.6) 30.4 % 1.00 [ -0.54, 2.54 ]
Total (95% CI) 63 62 100.0 % 0.65 [ -0.20, 1.50 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Global cognitive functioning, Outcome 4 MMSE after 2 months ERT or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 4 MMSE after 2 months ERT or placebo
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After E2 (0.05 mg transdermal) or placebo (Asthana 1999)
Asthana 1999 6 -1 (4.5) 6 0.83 (5.77) 10.9 % -0.33 [ -1.47, 0.82 ]
Subtotal (95% CI) 6 6 10.9 % -0.33 [ -1.47, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 After CEE (0.625 mg + 1.25 mg combined) (Mulnard 2000)
Mulnard 2000 81 -0.7 (2.7) 35 -1.7 (3.1) 89.1 % 0.35 [ -0.05, 0.75 ]
Subtotal (95% CI) 81 35 89.1 % 0.35 [ -0.05, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
Total (95% CI) 87 41 100.0 % 0.28 [ -0.10, 0.65 ]
Heterogeneity: Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =17%
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Analysis 1.5. Comparison 1 Global cognitive functioning, Outcome 5 MMSE after 3-6 months CEE (0.625 +
1.25 mg) or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 5 MMSE after 3-6 months CEE (0.625 + 1.25 mg) or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -1.4 (3.2) 32 -2.2 (4.1) 51.5 % 0.80 [ -0.82, 2.42 ]
Wang 2000 24 0.2 (3.3) 23 0.2 (2.5) 48.5 % 0.0 [ -1.67, 1.67 ]
Total (95% CI) 89 55 100.0 % 0.41 [ -0.75, 1.57 ]
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Global cognitive functioning, Outcome 6 MMSE after 12 months with (0.625 mg
+ 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 6 MMSE after 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -2.7 (3.7) 32 -3.1 (4.1) 100.0 % 0.40 [ -1.28, 2.08 ]
Total (95% CI) 65 32 100.0 % 0.40 [ -1.28, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Global cognitive functioning, Outcome 7 ADAS-Cog after 1-2 months with
(0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 7 ADAS-Cog after 1-2 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 19 -0.2 (4.8) 17 1.2 (6.15) 18.9 % -1.40 [ -5.03, 2.23 ]
Mulnard 2000 81 -0.8 (4.5) 35 -1.6 (4.4) 81.1 % 0.80 [ -0.96, 2.56 ]
Total (95% CI) 100 52 100.0 % 0.38 [ -1.20, 1.96 ]
Heterogeneity: Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Global cognitive functioning, Outcome 8 ADAS-Cog after 4-6 months with
(0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 8 ADAS-Cog after 4-6 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 17 1.8 (5.23) 17 0.5 (7) 26.2 % 1.30 [ -2.85, 5.45 ]
Mulnard 2000 65 -3.6 (6.3) 32 -2.6 (5.6) 73.8 % -1.00 [ -3.47, 1.47 ]
Total (95% CI) 82 49 100.0 % -0.40 [ -2.52, 1.73 ]
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Global cognitive functioning, Outcome 9 ADAS-Cog after 12 months with
(0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 9 ADAS-Cog after 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -5.6 (7.3) 32 -3.6 (4.7) 100.0 % -2.00 [ -4.41, 0.41 ]
Total (95% CI) 65 32 100.0 % -2.00 [ -4.41, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Global cognitive functioning, Outcome 10 ADAS-Cog after 12 months with
0.625 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 10 ADAS-Cog after 12 months with 0.625 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 35 -6.3 (8.7) 32 -3.6 (4.7) 100.0 % -2.70 [ -6.01, 0.61 ]
Total (95% CI) 35 32 100.0 % -2.70 [ -6.01, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Global cognitive functioning, Outcome 11 ADAS-Cog after 12 months with
1.25 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 11 ADAS-Cog after 12 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 30 -4.8 (5.4) 32 -3.6 (4.7) 100.0 % -1.20 [ -3.73, 1.33 ]
Total (95% CI) 30 32 100.0 % -1.20 [ -3.73, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Global cognitive functioning, Outcome 12 Blessed (BIMC) after 2-9 months
ERT or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 12 Blessed (BIMC) after 2-9 months ERT or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 after 2 months E2 (0.05 mg transdermal) or placebo
Asthana 1999 6 0.8 (6.33) 6 0.6 (10.1) 41.7 % 0.20 [ -9.34, 9.74 ]
Subtotal (95% CI) 6 6 41.7 % 0.20 [ -9.34, 9.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 after 9 months 0.625 mg CEE +MPA or placebo
Birge 1997 9 -4.69 (8.43) 9 1.55 (9.02) 58.3 % -6.24 [ -14.31, 1.83 ]
Subtotal (95% CI) 9 9 58.3 % -6.24 [ -14.31, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 15 15 100.0 % -3.55 [ -9.71, 2.60 ]
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
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Analysis 1.13. Comparison 1 Global cognitive functioning, Outcome 13 HDS-R after 16 weeks (estrogen) or
vitamin B1 as placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 1 Global cognitive functioning
Outcome: 13 HDS-R after 16 weeks (estrogen) or vitamin B1 as placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhang 2006 21 6.12 (8.57) 20 0.03 (8.11) 100.0 % 6.09 [ 0.98, 11.20 ]
Total (95% CI) 21 20 100.0 % 6.09 [ 0.98, 11.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Memory tests, Outcome 1 Paragraph recall (immediate + delayed) after 2
months with E2 transdermal or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 1 Paragraph recall (immediate + delayed) after 2 months with E2 transdermal or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Asthana 1999 6 -0.1 (3.34) 6 1.1 (6.41) 100.0 % -1.20 [ -6.98, 4.58 ]
Total (95% CI) 6 6 100.0 % -1.20 [ -6.98, 4.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours controls Favours treatment
32Hormone replacement therapy to maintain cognitive function in women with dementia (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Memory tests, Outcome 2 Paragraph recall (immediate) after 1 month with
1.25 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 2 Paragraph recall (immediate) after 1 month with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 21 0.1 (2.41) 18 -0.42 (2.39) 100.0 % 0.52 [ -0.99, 2.03 ]
Total (95% CI) 21 18 100.0 % 0.52 [ -0.99, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Memory tests, Outcome 3 Paragraph recall (delayed) after 1 month with 1.25
mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 3 Paragraph recall (delayed) after 1 month with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 21 -0.19 (0.4) 19 0.26 (0.65) 100.0 % -0.45 [ -0.79, -0.11 ]
Total (95% CI) 21 19 100.0 % -0.45 [ -0.79, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Memory tests, Outcome 4 Paragraph recall immediate after 4 months with
1.25 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 4 Paragraph recall immediate after 4 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 17 0.47 (3.46) 18 -1.11 (3.01) 100.0 % 1.58 [ -0.57, 3.73 ]
Total (95% CI) 17 18 100.0 % 1.58 [ -0.57, 3.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Memory tests, Outcome 5 Paragraph recall (delayed) after 4 months with 1.25
mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 5 Paragraph recall (delayed) after 4 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 16 0.44 (1.26) 18 -0.39 (1.38) 100.0 % 0.83 [ -0.06, 1.72 ]
Total (95% CI) 16 18 100.0 % 0.83 [ -0.06, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Memory tests, Outcome 6 Busche Selective Reminding (delayed recall) after 2
months with E2 transdermal or place.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 6 Busche Selective Reminding (delayed recall) after 2 months with E2 transdermal or place
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BSRT delayed recall score (1999)
Asthana 1999 6 7.7 (2.42) 6 1.2 (1.89) 100.0 % 6.50 [ 4.04, 8.96 ]
Total (95% CI) 6 6 100.0 % 6.50 [ 4.04, 8.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.19 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Memory tests, Outcome 7 Buschke Selective Reminding (Ir, IR+DR) after 2
months with E2 transdermal or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 7 Buschke Selective Reminding (Ir, IR+DR) after 2 months with E2 transdermal or placebo
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Sub-category
Asthana 1999 6 2.5 (5.19) 6 0.8 (12.5) 38.6 % 0.16 [ -0.97, 1.30 ]
Asthana 2001 10 8.28 (2.26) 10 7 (1.99) 61.4 % 0.58 [ -0.32, 1.47 ]
Total (95% CI) 16 16 100.0 % 0.42 [ -0.29, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
-4 -2 0 2 4
Favours controls Favours treatment
35Hormone replacement therapy to maintain cognitive function in women with dementia (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.8. Comparison 2 Memory tests, Outcome 8 CERAD word list after 9 months with 0.625 mg CEE
+ MPA or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 8 CERAD word list after 9 months with 0.625 mg CEE + MPA or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Birge 1997 8 0.02 (2.49) 8 0.69 (1.97) 100.0 % -0.67 [ -2.87, 1.53 ]
Total (95% CI) 8 8 100.0 % -0.67 [ -2.87, 1.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Memory tests, Outcome 9 Paired Associate word learning after 9 months with
0.625 mg CEE + MPA or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 9 Paired Associate word learning after 9 months with 0.625 mg CEE + MPA or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Birge 1997 11 -0.15 (4.04) 9 -2.58 (3.64) 100.0 % 2.43 [ -0.94, 5.80 ]
Total (95% CI) 11 9 100.0 % 2.43 [ -0.94, 5.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Memory tests, Outcome 10 Verbal Fluency tests (semantic memory).
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 10 Verbal Fluency tests (semantic memory)
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Category fluency after 4 months with 1.25 mg CEE or placebo
Henderson 2000 18 -2.11 (3.63) 18 -1.78 (4.92) 29.9 % -0.07 [ -0.73, 0.58 ]
Subtotal (95% CI) 18 18 29.9 % -0.07 [ -0.73, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
2 Category Fluency after 12 months with 0.625 + 1.25 mg CEE or placebo
Mulnard 2000 65 -5.7 (7.6) 32 -2.9 (6.6) 70.1 % -0.38 [ -0.81, 0.05 ]
Subtotal (95% CI) 65 32 70.1 % -0.38 [ -0.81, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Total (95% CI) 83 50 100.0 % -0.29 [ -0.65, 0.07 ]
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 2.11. Comparison 2 Memory tests, Outcome 11 Visual Retention Test (WMS) after 2 months of E2
transdermal or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 11 Visual Retention Test (WMS) after 2 months of E2 transdermal or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 VRT (immediate + delayed) after 2 months with E2 transdermal and placebo
Asthana 1999 6 0.9 (5.47) 6 -4.1 (27.7) 100.0 % 5.00 [ -17.59, 27.59 ]
Total (95% CI) 6 6 100.0 % 5.00 [ -17.59, 27.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Memory tests, Outcome 12 Visual Retention Test (WMS) after 1.25 mg CEE
or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 12 Visual Retention Test (WMS) after 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 VRT (immediate) after 1 month with 1.25 mg CEE or placebo
Henderson 2000 21 0.81 (6.74) 18 -0.78 (5.95) 6.8 % 1.59 [ -2.39, 5.57 ]
Subtotal (95% CI) 21 18 6.8 % 1.59 [ -2.39, 5.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 VRT (delayed) after 1 month with 1.25 mg CEE or placebo
Henderson 2000 17 0.3 (2.74) 16 0.16 (1.42) 49.6 % 0.14 [ -1.34, 1.62 ]
Subtotal (95% CI) 17 16 49.6 % 0.14 [ -1.34, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 VRT (immediate) after 4 months with 1.25 mg CEE or placebo
Henderson 2000 18 -1.44 (8.04) 17 -1.35 (5.67) 5.1 % -0.09 [ -4.68, 4.50 ]
Subtotal (95% CI) 18 17 5.1 % -0.09 [ -4.68, 4.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
4 VRT (delayed) after 4 months with 1.25 mg CEE or placebo
Henderson 2000 18 -0.11 (2.3) 18 0.44 (2.81) 38.4 % -0.55 [ -2.23, 1.13 ]
Subtotal (95% CI) 18 18 38.4 % -0.55 [ -2.23, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 74 69 100.0 % -0.04 [ -1.08, 1.00 ]
Heterogeneity: Chi2 = 1.06, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 1.06, df = 3 (P = 0.79), I2 =0.0%
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Analysis 2.13. Comparison 2 Memory tests, Outcome 13 Visual span foward after 4 months of 1.25 mg CEE
or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 13 Visual span foward after 4 months of 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 18 -0.72 (1.67) 18 0 (1.08) 100.0 % -0.72 [ -1.64, 0.20 ]
Total (95% CI) 18 18 100.0 % -0.72 [ -1.64, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Memory tests, Outcome 14 Face recognition after 12 months of 0.625 + 1.25
mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 14 Face recognition after 12 months of 0.625 + 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -9.7 (14.2) 32 -5.7 (22.4) 100.0 % -4.00 [ -12.49, 4.49 ]
Total (95% CI) 65 32 100.0 % -4.00 [ -12.49, 4.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Memory tests, Outcome 15 Digit span forward (STM and concentration).
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 15 Digit span forward (STM and concentration)
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Digit Span foward after 4 months with 1.25 mg CEE + MPA or placebo
Henderson 2000 18 -0.28 (1.13) 18 0.56 (1.65) 70.2 % -0.58 [ -1.25, 0.09 ]
Subtotal (95% CI) 18 18 70.2 % -0.58 [ -1.25, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
2 Digit Span forward after 9 months with 0.625 mg CEE+MPA or placebo
Birge 1997 8 -0.05 (1.42) 7 0.53 (1.52) 29.8 % -0.37 [ -1.40, 0.65 ]
Subtotal (95% CI) 8 7 29.8 % -0.37 [ -1.40, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 26 25 100.0 % -0.52 [ -1.08, 0.04 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 2.16. Comparison 2 Memory tests, Outcome 16 Other memory tests.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 2 Memory tests
Outcome: 16 Other memory tests
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CASI LTM after 1,5 week with 1.25 mg CEE or placebo
Wang 2000 24 0.3 (1.3) 23 -0.3 (2.3) 70.6 % 0.32 [ -0.26, 0.89 ]
Subtotal (95% CI) 24 23 70.6 % 0.32 [ -0.26, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Visual memory adaptation Rey test Immediate recall after 2 months of transdemral E2 or placebo
Asthana 2001 10 26.67 (9.5) 10 21.67 (10.55) 29.4 % 0.48 [ -0.41, 1.37 ]
Subtotal (95% CI) 10 10 29.4 % 0.48 [ -0.41, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 34 33 100.0 % 0.36 [ -0.12, 0.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 3.1. Comparison 3 Language tests, Outcome 1 Token test after 1-2 months of HRT or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 3 Language tests
Outcome: 1 Token test after 1-2 months of HRT or placebo
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Token test after 1 months with 1.25 mg CEE and placebo
Henderson 2000 17 0.41 (8.62) 16 1 (3.63) 73.9 % -0.09 [ -0.77, 0.60 ]
Subtotal (95% CI) 17 16 73.9 % -0.09 [ -0.77, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 Token test after 2 months with E2 transdermal or placebo
Asthana 1999 6 0.8 (2.2) 6 -0.3 (2.72) 26.1 % 0.41 [ -0.74, 1.56 ]
Subtotal (95% CI) 6 6 26.1 % 0.41 [ -0.74, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 23 22 100.0 % 0.04 [ -0.54, 0.63 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 3.2. Comparison 3 Language tests, Outcome 2 Token test after 4 months with 1.25 mg CEE or
placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 3 Language tests
Outcome: 2 Token test after 4 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 16 1.44 (4.86) 15 1 (5.93) 100.0 % 0.44 [ -3.39, 4.27 ]
Total (95% CI) 16 15 100.0 % 0.44 [ -3.39, 4.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Language tests, Outcome 3 Boston Naming Test after 4 months with 1.25 mg
CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 3 Language tests
Outcome: 3 Boston Naming Test after 4 months with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 18 0.61 (6.41) 18 -0.17 (4.85) 100.0 % 0.78 [ -2.93, 4.49 ]
Total (95% CI) 18 18 100.0 % 0.78 [ -2.93, 4.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Speed of information processing and concentration tests, Outcome 1 TMT-A
after 1 month with 1.25 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 1 TMT-A after 1 month with 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 21 -31.2 (83.4) 19 0.32 (34.4) 100.0 % -31.52 [ -70.40, 7.36 ]
Total (95% CI) 21 19 100.0 % -31.52 [ -70.40, 7.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Speed of information processing and concentration tests, Outcome 2 TMT-A
after > 2 months HRT or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 2 TMT-A after > 2 months HRT or placebo
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 TMT-A (time) after 2 months with E2 transdermal or placebo
Asthana 1999 6 -10 (69.1) 6 30 (225) 7.8 % -0.22 [ -1.36, 0.91 ]
Subtotal (95% CI) 6 6 7.8 % -0.22 [ -1.36, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
2 TMT-A (time) after 4-12 months with (0.625 mg + 1.25 mg) CEE or placebo
Henderson 2000 18 -10.5 (75.3) 18 -6.89 (56.8) 23.5 % -0.05 [ -0.71, 0.60 ]
Mulnard 2000 65 18.9 (48.6) 32 18.6 (43.4) 56.1 % 0.01 [ -0.42, 0.43 ]
Subtotal (95% CI) 83 50 79.6 % -0.01 [ -0.37, 0.34 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
3 TMT-A (lines/sec, reversed) after 9 months with 0.625 mg CEE + MPA or placebo
Birge 1997 11 -0.03 (0.29) 9 0.08 (0.23) 12.6 % -0.40 [ -1.29, 0.49 ]
Subtotal (95% CI) 11 9 12.6 % -0.40 [ -1.29, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 100 65 100.0 % -0.08 [ -0.39, 0.24 ]
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
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Analysis 4.3. Comparison 4 Speed of information processing and concentration tests, Outcome 3 TMT-B
after 1 month with CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 3 TMT-B after 1 month with CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 18 -17.4 (57.8) 18 23.5 (59.7) 100.0 % -40.90 [ -79.29, -2.51 ]
Total (95% CI) 18 18 100.0 % -40.90 [ -79.29, -2.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Speed of information processing and concentration tests, Outcome 4 TMT-B
after > 2 months.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 4 TMT-B after > 2 months
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 TMT-B after 4 months with 1.25 mg CEE or placebo
Henderson 2000 18 -8.44 (51.6) 18 9.78 (57.5) 64.2 % -0.33 [ -0.98, 0.33 ]
Subtotal (95% CI) 18 18 64.2 % -0.33 [ -0.98, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
2 TMT-B after 9 months with 0.625 mg CEE + MPA or placebo
Birge 1997 11 0 (0.14) 9 0 (0.1) 35.8 % 0.0 [ -0.88, 0.88 ]
Subtotal (95% CI) 11 9 35.8 % 0.0 [ -0.88, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 29 27 100.0 % -0.21 [ -0.74, 0.32 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 4.5. Comparison 4 Speed of information processing and concentration tests, Outcome 5 Stroop
after 2 months with E2 transdermal or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 5 Stroop after 2 months with E2 transdermal or placebo
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asthana 1999 6 -8 (11.7) 6 -11 (68.5) 38.0 % 0.06 [ -1.08, 1.19 ]
Asthana 2001 10 92.86 (28.21) 10 107.14 (45.14) 62.0 % -0.36 [ -1.25, 0.52 ]
Total (95% CI) 16 16 100.0 % -0.20 [ -0.90, 0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
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Analysis 4.6. Comparison 4 Speed of information processing and concentration tests, Outcome 6 DSST
after 12 months with (0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 6 DSST after 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -3.4 (7.7) 32 -3.9 (6.8) 100.0 % 0.50 [ -2.51, 3.51 ]
Total (95% CI) 65 32 100.0 % 0.50 [ -2.51, 3.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Speed of information processing and concentration tests, Outcome 7 Letter
Cancellation test after 12 months with (0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 7 Letter Cancellation test after 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 -1.4 (7.5) 32 -1.3 (5.5) 100.0 % -0.10 [ -2.74, 2.54 ]
Total (95% CI) 65 32 100.0 % -0.10 [ -2.74, 2.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Speed of information processing and concentration tests, Outcome 8 Finger
tapping after 12 months with (0.625 mg + 1.25 mg) CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 8 Finger tapping after 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mulnard 2000 65 0.1 (8.8) 32 4 (9.6) 100.0 % -3.90 [ -7.85, 0.05 ]
Total (95% CI) 65 32 100.0 % -3.90 [ -7.85, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Speed of information processing and concentration tests, Outcome 9 Digit
Span backwards after 1 month of 1.25 mg CEE or placebo.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 9 Digit Span backwards after 1 month of 1.25 mg CEE or placebo
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henderson 2000 21 0.71 (2.24) 19 -0.05 (1.35) 100.0 % 0.76 [ -0.37, 1.89 ]
Total (95% CI) 21 19 100.0 % 0.76 [ -0.37, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Speed of information processing and concentration tests, Outcome 10 Digit
Span backwards after > 4 months of CEE.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 4 Speed of information processing and concentration tests
Outcome: 10 Digit Span backwards after > 4 months of CEE
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Digit span after 4 months with 1.25 mg CEE or placebo
Henderson 2000 18 0.44 (1.46) 18 -0.44 (1.1) 65.3 % 0.67 [ -0.01, 1.34 ]
Subtotal (95% CI) 18 18 65.3 % 0.67 [ -0.01, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
2 Digit Span after 9 months with 0.625 mg CEE + MPA or placebo
Birge 1997 9 -0.75 (1.82) 9 -0.71 (1.82) 34.7 % -0.02 [ -0.94, 0.90 ]
Subtotal (95% CI) 9 9 34.7 % -0.02 [ -0.94, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
Total (95% CI) 27 27 100.0 % 0.43 [ -0.12, 0.97 ]
Heterogeneity: Chi2 = 1.39, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
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Analysis 5.1. Comparison 5 Clinical impressions of change scales, Outcome 1 CGIC (score of 4=no change
from baseline, higher=worse).
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 5 Clinical impressions of change scales
Outcome: 1 CGIC (score of 4=no change from baseline, higher=worse)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 after 1 month with 1.25 mg CEE or placebo
Henderson 2000 19 3.9 (0.44) 19 3.8 (0.44) 71.2 % 0.10 [ -0.18, 0.38 ]
Subtotal (95% CI) 19 19 71.2 % 0.10 [ -0.18, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 After 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Mulnard 2000 65 5.1 (0.9) 32 5 (1.1) 28.8 % 0.10 [ -0.34, 0.54 ]
Subtotal (95% CI) 65 32 28.8 % 0.10 [ -0.34, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Total (95% CI) 84 51 100.0 % 0.10 [ -0.14, 0.34 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.2. Comparison 5 Clinical impressions of change scales, Outcome 2 CDR (higher=worse).
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 5 Clinical impressions of change scales
Outcome: 2 CDR (higher=worse)
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1,5 months with 1.25 mg CEE or placebo
Wang 2000 24 0 (0.3) 23 0 (0.4) 36.2 % 0.0 [ -0.57, 0.57 ]
Subtotal (95% CI) 24 23 36.2 % 0.0 [ -0.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 After 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Mulnard 2000 65 0.5 (0.6) 32 0.2 (0.4) 63.8 % 0.55 [ 0.12, 0.98 ]
Subtotal (95% CI) 65 32 63.8 % 0.55 [ 0.12, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.013)
Total (95% CI) 89 55 100.0 % 0.35 [ 0.01, 0.69 ]
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Chi2 = 2.25, df = 1 (P = 0.13), I2 =56%
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Analysis 5.3. Comparison 5 Clinical impressions of change scales, Outcome 3 CIBIC.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 5 Clinical impressions of change scales
Outcome: 3 CIBIC
Study or subgroup Treatment Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1,5 month with 1.25 mg CEE or placebo
Wang 2000 24 -0.2 (0.9) 23 -0.2 (0.8) 76.2 % 0.0 [ -0.57, 0.57 ]
Subtotal (95% CI) 24 23 76.2 % 0.0 [ -0.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 After 9 months with 0.625 mg CEE + MPA or placebo
Birge 1997 8 3.5 (1.07) 9 4.44 (0.73) 23.8 % -0.99 [ -2.01, 0.04 ]
Subtotal (95% CI) 8 9 23.8 % -0.99 [ -2.01, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Total (95% CI) 32 32 100.0 % -0.23 [ -0.73, 0.27 ]
Heterogeneity: Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 2.71, df = 1 (P = 0.10), I2 =63%
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Analysis 6.1. Comparison 6 Depression scales, Outcome 1 HDRS.
Review: Hormone replacement therapy to maintain cognitive function in women with dementia
Comparison: 6 Depression scales
Outcome: 1 HDRS
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3 months with 1.25 mg CEE or placebo
Wang 2000 24 -1.2 (5.8) 23 0.4 (4.8) 9.5 % -1.60 [ -4.64, 1.44 ]
Subtotal (95% CI) 24 23 9.5 % -1.60 [ -4.64, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 After 12 months with (0.625 mg + 1.25 mg) CEE or placebo
Mulnard 2000 65 0.2 (4) 32 0 (0.39) 90.5 % 0.20 [ -0.78, 1.18 ]
Subtotal (95% CI) 65 32 90.5 % 0.20 [ -0.78, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 89 55 100.0 % 0.03 [ -0.90, 0.96 ]
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 1.22, df = 1 (P = 0.27), I2 =18%
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A P P E N D I C E S
Appendix 1. List of abbreviations and their definitions
AD, Alzheimer’s disease
Blessed or BIMC, Blessed Information Memory and Concentration test
BSRT, Buschke’s Selective Reminding Test
BSO, Bilateral Salpingo-Oopherectomy (removal of the ovaries)
BVRT, Benton Visual Retention Test
CEE, Conjugated Equine Estrogens or Premarin
CVLT, Californian Verbal Learning Test
DAT, Dementia of the Alzheimer’s Type
Dep, depressed
DSM, Diagnostic Statistical Manual
DSST, Digit Symbol Substitution Test
E1, Estrone
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E2, Estradiol
E3, Estriol
ERT, Estrogen Replacement Therapy
HRT, Hormone Replacement Therapy (estrogen plus progestagen)
I.M., Intramuscular
MANOVA, Multivariate Analysis of Variance
MMSE, Mini-Mental Status Examination
MPA, Medroxyprogesterone Acetate
NINCDS/ADRDA, National Institute of Neurological and Communicative Disorders and the Alzheimer’s Disease and Related Dis-
orders Association
RCT, Randomized Controlled Trial
SD, Standard Deviation
SEM, Standard Error of the Mean
SQRT, Square Root
TMT, Trail Making Test
VaD, Vascular Dementia
Var, Variance
VRT WMS, Visual Retention Test of the WMS (Visuospatial Memory)
WHI, the Women’s Health Initiative study
WISDOM, Women’s International Study of long Duration Oestrogen after the Menopause
WMD, Weighted Mean Difference
WMS, Wechsler Memory Scale
WH A T ’ S N E W
Last assessed as up-to-date: 8 April 2008.
Date Event Description
12 May 2008 Amended Converted to new review format.
9 April 2008 New citation required and conclusions have changed An update search of the literature review was done using
Cochrane methods on 7 November 2007. The main author
(EH) ran additional searches in MEDLINE using the key-
words hrt, ert, estr* and Alzheimer* or dementia in April
2008. In addition experts in the field were asked whether
they had any knowledge of trials that had been published or
were ongoing.
Professor Asthana kindly sent us his own papers but knew
of no other studies.
We included two studies by Asthana et al. (2001) and Zhang
et al. (2006), which was translated from Chinese.
All studies which included SERMS and non-estrogenic com-
pounds (GH, DHEA, corticosteroids, etc.) were excluded
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-Contact editor for this review is Leon Flicker.
-Consumer editor for this review is Clare Bateman.
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